Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 2/20 | 0.48 |
| ▸ | FLT3 | P36888 | 15/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7609640 | 1.00 | ALDH1A1 (0.49) | ALDH1A1LMNAHPGDPDE5AFLT3 | |
| SCHEMBL7610846 | 0.82 | ALDH1A1 (0.50) | ALDH1A1LMNAHPGDPDE5AFLT3 | |
| SCHEMBL7610843 | 0.82 | ALDH1A1 (0.50) | ALDH1A1LMNAHPGDPDE5AFLT3 | |
| SCHEMBL7610184 | 0.82 | GBA1 (0.50) | ALDH1A1LMNAHPGDPDE5AFLT3 | |
| SCHEMBL7610192 | 0.82 | GBA1 (0.50) | ALDH1A1LMNAHPGDPDE5AFLT3 | |
| SCHEMBL7605565 | 0.81 | FLT3 (0.49) | ALDH1A1LMNAHPGDPDE5AFLT3 | |
| SCHEMBL7605570 | 0.81 | FLT3 (0.49) | ALDH1A1LMNAHPGDPDE5AFLT3 | |
| SCHEMBL7608497 | 0.79 | GBA1 (0.52) | ALDH1A1LMNAHPGDPDE5AGBA1 | |
| SCHEMBL4698518 | 0.78 | PDE5A (0.79) | ALDH1A1LMNAPDE5AGBA1 | |
| SCHEMBL5595373 | 0.78 | PDE5A (0.79) | ALDH1A1LMNAPDE5AGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | OSI PHARMACEUTICALS, INC. | 2002-02-28 | — | — | US | disclosed |
| US-5439895-A | Cardiovascular disorders; inhibitor of thromboxane A2 synthetase and cyclic guanosine 3',5'-monophosphate | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | VHL, MCL1, NFATC1 | ALDH1A1 1566/4885LMNA 902/4885HPGD 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.